The UK Health Research Authority (HRA) has published the results of a pilot project dedicated to the development and submission of Inclusivity and Diversity Plans by researchers and sponsors of clinical trials and clinical studies of medicinal products. The pilot project aimed to assess how effectively participants in the clinical trial process could plan and document measures to ensure diversity among research participants. Inclusivity and Diversity Plans involve taking into account various demographic groups — by age, gender, ethnicity, and other characteristics — when recruiting participants for clinical drug trials. The publication of the pilot results is part of broader work to increase the representativeness of clinical research, which should contribute to obtaining more accurate data on the safety and efficacy of drugs for various population groups. Historically, clinical trial participants often did not reflect the full diversity of the population, which could lead to gaps in understanding how medicines work across different demographic groups. The HRA, which acts as the regulator in the field of medical research in the UK, views the pilot project results as a foundation for further improvement of inclusivity requirements in clinical trials. It is expected that the conclusions drawn from the pilot will help adjust approaches to developing such plans and increase their practical applicability for researchers and sponsors in the future.